Emmie de Wit joins TWiV to explain her work on the pathogenesis of infection with SARS-CoV-2 in rhesus macaques, including studies on remdesivir and vaccine candidate.
Jon Yewdell returns to explain studies on detection of antibodies and T cell epitopes in patients who have recovered from COVID-19.
Raul Rabadan joins TWiV to explain the use of computational biology to demonstrate how recombination and mutation led to emergence of SARS-CoV-2.
Daniel Griffin provides a clinical update on COVID-19, then we review TETRIS by Paterson NJ, modeling the effects of intervention in the US on cases and deaths, mixing PCR and serology data, and much more, including listener email.
Vincent, Kathy and Rich discuss COVID-19 research paper overload, Moderna’s mRNA vaccine Phase I results, increase of ACE2 RNA by cigarette smoke, and answer listener questions.
Daniel Griffin provides a clinical update on COVID-19, then we review results showing requirement for the furin site in the SARS-CoV-2 spike for replication, US state vaccine exemptions, concerns with a rapid diagnostic test, and answers to listener questions.
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions.
Daniel Griffin provides a weekly clinical update on COVID-19, then Michael Schmidt discusses how dentistry can be safely practiced during a pandemic, followed by answers to listener questions.
The TWiV team summarizes serology-based tests for SARS-CoV-2, lack of effect of ACE inhibitors or ARBs on COVID-19 severity, and answers listener questions.
Susan Weiss recalls some of her 40 years of research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.